PRINCETON, New JerseyThe FDA has granted priority review to dasatinib(Drug information on dasatinib) (BMS-354825), developed by Bristol-Myers Squibb, for treatment of imatinib(Drug information on imatinib) (Gleevec)-resistant or refractory chronic myelogenous leukemia (CML) in adults. Dasatinib, an oral, small-molecule tyrosine kinase inhibitor, exhibits greater potency than imatinib and inhibits the majority of kinase mutations resistant to imatinib. The new drug application also seeks approval of dasatinib for treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
